AccessibilityHelp

Lycia Therapeutics(NASDAQ) LYCA

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
$29.83
+65.72%
+11.83Today
After hours$28.15-$1.68 (-5.63%)

Lycia Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$29.83

Volume

2,281,522.472

Open

$28.55

Previous Close

$30.00

Daily Range

$22.19 - $36.49

52-Week Range

$22.19 - $36.49

Estimated Earnings Date

N/A

LYCA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lycia Therapeutics

Lycia Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics aimed at degrading disease-causing extracellular proteins. The company primarily targets autoimmune, inflammatory, and allergic diseases, showcasing a commitment to addressing significant healthcare challenges.

Products and Services
  • Novel therapeutics designed to degrade harmful extracellular proteins
  • Focus on autoimmune, inflammatory, and allergic disease treatments
  • Clinical-stage development with potential for groundbreaking therapies
Growth Outlook
  • Founded in 2019, demonstrating rapid growth potential in biotechnology
  • Headquartered in South San Francisco, a hub for biotech innovation
  • Strong pipeline of therapeutics could lead to significant market opportunities
Financial Highlights
  • Market capitalization of approximately $1.54 billion indicates strong investor interest
  • Stock price range between $22.19 and $36.275 reflects market confidence
  • Average trading volume of over 869,000 shares suggests active investor engagement
Lycia Therapeutics Inc. operates in a dynamic sector with a clear focus on addressing critical health issues through innovative solutions. The company's strategic positioning in South San Francisco, combined with its clinical-stage pipeline, offers promising growth potential. The financial highlights indicate a robust market presence, with a significant market capitalization and active trading volume, reflecting investor confidence in the company's future. As the biotechnology landscape continues to evolve, Lycia Therapeutics stands out as a noteworthy player with the potential to make a meaningful impact in the healthcare sector.
AI Generated • Oct 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

65

CEO

Aetna Wun Trombley, PhD

Website

lyciatx.com

Headquarters

South San Francisco, CA 94080, US

LYCA Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

2.28M

Avg. Volume

0

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Lycia Therapeutics Performance Analysis

Lycia Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 14,936,000N/A
20252025-12-31USD 6,741,000-54.9%
Lycia Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -0.51N/A
20252025-12-31USD -0.7037.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,635.64-0.00%
^DJIDJI
$52,319.47-0.01%
^IXICNASDAQ
$26,002.43-0.00%
BTCBitcoin
$81,534.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About LYCA

What is the current price of Lycia Therapeutics?

Lycia Therapeutics is trading at $30.00 per share.

What is the 52-week range for Lycia Therapeutics?

Over the past 52 weeks, Lycia Therapeutics has traded between $22.19 and $36.49.

How much debt does Lycia Therapeutics have?

As of the most recent reporting period, Lycia Therapeutics reported total debt of $205.09M.

How much cash does Lycia Therapeutics have on hand?

Lycia Therapeutics reported $19.27M in cash and cash equivalents in its most recent financial results.

What is Lycia Therapeutics’s dividend yield?

Lycia Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services